Ekso Bionics’ Strong Q3 2025 Recovery and Strategic Prospects Lead to Buy Rating
Analyst Swayampakula Ramakanth of H.C. Wainwright maintains a Buy rating on Ekso Bionics, with a $6 price target. The rating is based on strong Q3 2025 sales recovery, improved margins, and strategic prospects. Despite previous order delays, the company shows resilience, exceeding revenue estimates and reducing net loss per share. Strategic transactions are being explored, though outcomes are uncertain. The analyst's valuation supports confidence in future performance despite commercial, clinical, and regulatory risks.
Analyst Swayampakula Ramakanth of H.C. Wainwright maintained a Buy rating on EKSO BIONICS, with a price target of $6.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Swayampakula Ramakanth has given his Buy rating due to a combination of factors including a significant recovery in Ekso Bionics’ quarterly sales and improved gross margins. The company reported a strong sequential growth in revenue for the third quarter of 2025, which rebounded from a previous quarter that had underperformed due to specific order delays. This recovery suggests that the earlier issues were unique and not indicative of a broader trend.
Additionally, Ekso Bionics is exploring strategic transactions that could potentially enhance its business operations, although the outcome and timeline of these transactions remain uncertain. Financially, the company has shown resilience by exceeding consensus revenue estimates and reducing its net loss per share. The analyst’s valuation, which includes various financial models, supports a 12-month price target increase to $6, reflecting confidence in the company’s future performance despite existing risks such as commercial, clinical, and regulatory challenges.
